1.Li S, Zhang Y, Zhu CG, et al. Identification of familial hypercholesterolemia in patients with myocardial infarction: a Chinese cohort study[J]. Journal of clinical lipidology, 2016, 10(6): 1344-1352.
2.Nordestgaard BG, Chapman MJ, Humphries SE et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J, 2013; 34: 3478–3490a.
3.Li S, Zhang HW, Guo YL, et al. Familial hypercholesterolemia in very young myocardial infarction[J]. Scientific reports, 2018, 8(1): 1-8.
4.Liu MM, Peng J, Guo YL, et al. Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia[J]. Journal of translational medicine, 2021, 19(1): 1-11.
5.Cao YX, Wu NQ, Sun D, et al. Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease[J]. Journal of translational medicine, 2018, 16(1): 1-9.
6.Cao YX, Sun D, Liu HH, et al. Improvement of definite diagnosis of familial hypercholesterolemia using an expanding genetic analysis[J]. JACC: Asia, 2021, 1(1): 82-89.
7.Li S, Wu NQ, Zhu CG, et al. Significance of lipoprotein (a) levels in familial hypercholesterolemia and coronary artery disease[J]. Atherosclerosis, 2017, 260: 67-74.
8.Sun D, Zhou BY, Zhao X, et al. Lipoprotein (a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia[J]. Journal of clinical laboratory analysis, 2018, 32(7): e22442.
9.Sun D, Li S, Zhao X, et al. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case‐control study[J]. Metabolism, 2018, 79: 33-41.
10.Cao YX, Liu HH, Sun D, et al. The different relations of PCSK9 and Lp (a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia[J]. Atherosclerosis, 2018, 277: 7-14.
11.Cao YX, Liu HH, Jin JL, et al. Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia[J]. European journal of preventive cardiology, 2021, 28(3): 272-279.
12.Cao YX, Sun D, Liu HH, et al. A Novel Modified System of Simplified Chinese Criteria for Familial Hypercholesterolemia (SCCFH)[J]. Molecular diagnosis & therapy, 2019, 23(4): 547-553.
13.Sun D, Cao YX, Li S, et al. A modified algorithm with lipoprotein (a) added for diagnosis of familial hypercholesterolemia[J]. Clinical cardiology, 2019, 42(10): 988-994.
14.Liu MM, Peng J, Guo YL, et al. Impact of diabetes on coronary severity and cardiovascular outcomes in patients with heterozygous familial hypercholesterolaemia[J]. European Journal of Preventive Cardiology, 2021, 28(16): 1807-1816.
15.Liu MM, Peng J, Guo YL, et al. SORBS2 as a molecular target for atherosclerosis in patients with familial hypercholesterolemia[J]. Journal of Translational Medicine, 2022, 20(1): 1-16.